Liver magnetic resonance imaging, non-alcoholic fatty liver disease and metabolic syndrome risk in pre-pubertal Mexican boys.
BMI
Metabolic syndrome
Multiparametric MRI
NAFLD
Obesity
Young children
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
30 10 2024
30 10 2024
Historique:
received:
06
03
2024
accepted:
21
10
2024
medline:
31
10
2024
pubmed:
31
10
2024
entrez:
31
10
2024
Statut:
epublish
Résumé
Rising global pediatric obesity rates, increase non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome (MetS) prevalence, with MetS being a NAFLD risk factor. NAFLD can be asymptomatic, with liver function tests insensitive to mild disease, and liver biopsy, risking complications. Thus, we investigated multiparametric MRI (mpMRI) metrics of liver fat (proton density fat fraction, PDFF) and disease activity (fibro-inflammation; iron-corrected T1, cT1), in a Hispanic pre-pubertal pediatric cohort, with increased risk of NAFLD. Pre-pubertal boys (n = 81) of varying Body-Mass Index (BMI) were recruited in Mexico City. Most children (81%) had normal liver transaminase levels, 38% had high BMI, and 14% had ≥ 3 MetS risk factors. Applying mpMRI thresholds, 12%, 7% and 4% of the cohort had NAFLD, NASH and high-risk NASH respectively. Participants with ≥ 3 MetS risk factors had higher cT1 (834 ms vs. 737 ms, p = 0.004) and PDFF (8.7% vs. 2.2%, p < 0.001) compared to those without risk factors. Those with elevated cT1 tended to have high BMI and high insulin (p = 0.005), HOMA-IR (p = 0.005) and leptin (p < 0.001). The significant association of increased risk of MetS with abnormal mpMRI, particularly cT1, proposes the potential of using mpMRI for routine pediatric NAFLD screening of high-risk (high BMI, high MetS risk score) populations.
Identifiants
pubmed: 39478096
doi: 10.1038/s41598-024-77307-8
pii: 10.1038/s41598-024-77307-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
26104Informations de copyright
© 2024. The Author(s).
Références
Younossi, Z. M. et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J. Hepatol. 71, 793–801. https://doi.org/10.1016/j.jhep.2019.06.021 (2019).
doi: 10.1016/j.jhep.2019.06.021
pubmed: 31279902
Saklayen, M. G. The global epidemic of the metabolic syndrome. Curr. Hypertens. Rep. 20, 12. https://doi.org/10.1007/s11906-018-0812-z (2018).
doi: 10.1007/s11906-018-0812-z
pubmed: 29480368
pmcid: 5866840
Parthasarathy, G., Revelo, X. & Malhi, H. Pathogenesis of nonalcoholic steatohepatitis: an overview. Hepatol. Commun. 4, 478–492. https://doi.org/10.1002/hep4.1479 (2020).
doi: 10.1002/hep4.1479
pubmed: 32258944
pmcid: 7109346
Fox, A., Feng, W. & Asal, V. What is driving global obesity trends? Globalization or “modernization”?. Glob. Health. 15, 32. https://doi.org/10.1186/s12992-019-0457-y (2019).
doi: 10.1186/s12992-019-0457-y
Aceves-Martins, M., Llauradó, E., Tarro, L., Solà, R. & Giralt, M. Obesity-promoting factors in Mexican children and adolescents: challenges and opportunities. Glob. Health Action. 9, 29625. https://doi.org/10.3402/gha.v9.29625 (2016).
doi: 10.3402/gha.v9.29625
pubmed: 26787421
Shamah-Levy, T. et al. Nutrition status of children, teenagers, and adults from National Health and Nutrition Surveys in Mexico From 2006 to 2020. Front. Nutr. 25, 777246. https://doi.org/10.3389/fnut.2021.777246 (2020).
doi: 10.3389/fnut.2021.777246
Kopp, W. How western diet and lifestyle drive the pandemic of obesity and civilization diseases. Diabetes Metab. Syndr. Obes. Targets Ther. 12, 2221–2236. https://doi.org/10.2147/DMSO.S216791 (2019).
doi: 10.2147/DMSO.S216791
Vos, M. B. et al. NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J. Pediatr. Gastroenterol. Nutr. 64, 319–334. https://doi.org/10.1097/MPG.0000000000001482 (2017).
doi: 10.1097/MPG.0000000000001482
pubmed: 28107283
pmcid: 5413933
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease, 2016. J. Hepatol. 64, 1388–1402. https://doi.org/10.1016/j.jhep.2015.11.004 (2016).
Hunter, A. K. & Lin, H. C. Review of clinical guidelines in the diagnosis of pediatric nonalcoholic fatty liver disease. Clin. Liver Dis. 18, 40–44. https://doi.org/10.1002/cld.1094 (2021).
doi: 10.1002/cld.1094
Bejarano, P. A., Koehler, A. & Sherman, K. E. Second opinion pathology in liver biopsy interpretation. Am. J. Gastroenterol. 96, 3158–3164. https://doi.org/10.1111/j.1572-0241.2001.05273.x (2001).
doi: 10.1111/j.1572-0241.2001.05273.x
pubmed: 11721765
Goldin, R. D. et al. Intra-observer and inter-observer variation in the histopathological assessment of chronic viral hepatitis. J. Hepatol. 25, 649–654. https://doi.org/10.1016/s0168-8278(96)80234-0 (1996).
doi: 10.1016/s0168-8278(96)80234-0
pubmed: 8938541
Ratziu, V. et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 128, 1898–1906. https://doi.org/10.1053/j.gastro.2005.03.084 (2005).
doi: 10.1053/j.gastro.2005.03.084
pubmed: 15940625
Thomaides-Brears, H. B. et al. Incidence of complications from percutaneous biopsy in chronic liver disease: a systematic review and meta-analysis. Dig. Dis. Sci. 67, 3366–3394. https://doi.org/10.1007/s10620-021-07089-w (2022).
doi: 10.1007/s10620-021-07089-w
pubmed: 34129125
Neuberger, J. & Cain, O. The need for alternatives to liver biopsies: non-invasive analytics and diagnostics. Hepatic Med. Evid. Res. 13, 59–69. https://doi.org/10.2147/HMER.S278076 (2021).
doi: 10.2147/HMER.S278076
Kwok, R. et al. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease—the role of transient elastography and plasma cytokeratin-18 fragments. Aliment. Pharmacol. Ther. 39, 254–269. https://doi.org/10.1111/apt.12569 (2014).
doi: 10.1111/apt.12569
pubmed: 24308774
da Silva, L. et al. Ultrasound elastography in patients with fatty liver disease. Radiol. Bras. 53, 47–55. https://doi.org/10.1590/0100-3984.2019.0028 (2020).
doi: 10.1590/0100-3984.2019.0028
pubmed: 32313337
pmcid: 7159044
British Society of Pediatric Gastroenterlogy Hepatology and Nutrition (BSPGHAN) Liver Steering Group. UK Fatty Liver Guideline August 2020. https://bspghan.org.uk/wp-content/uploads/2020/08/LSG_UK-Fatty-Liver-Guideline-August-2020.pdf (2020).
Janowski, K. et al. Quantitative multiparametric MRI as a non-invasive stratification tool in children and adolescents with autoimmune liver disease. Sci. Rep. 11, 15261. https://doi.org/10.1038/s41598-021-94754-9 (2021).
doi: 10.1038/s41598-021-94754-9
pubmed: 34315985
pmcid: 8316432
Janowski, K. et al. Multiparametric MRI as a noninvasive monitoring tool for children with autoimmune hepatitis. J. Pediatr. Gastroenterol. Nutr. 72, 108–114. https://doi.org/10.1097/MPG.0000000000002930 (2021).
doi: 10.1097/MPG.0000000000002930
pubmed: 32925554
Mahalingam, N. et al. Associations between MRI T1 mapping, liver stiffness, quantitative MRCP, and laboratory biomarkers in children and young adults with autoimmune liver disease. Abdom. Radiol. 47, 672–683. https://doi.org/10.1007/s00261-021-03378-0 (2022).
doi: 10.1007/s00261-021-03378-0
Rijnberg, F. M. et al. 4D flow cardiovascular magnetic resonance derived energetics in the Fontan circulation correlate with exercise capacity and CMR-derived liver fibrosis/congestion. J. Cardiovasc. Magn. Reson. 24, 21. https://doi.org/10.1186/s12968-022-00854-4 (2022).
doi: 10.1186/s12968-022-00854-4
pubmed: 35346249
pmcid: 8962091
Dillman, J. R. et al. Comparison of liver T1 relaxation times without and with iron correction in pediatric autoimmune liver disease. Pediatr. Radiol. 50, 935–942. https://doi.org/10.1007/s00247-020-04663-8 (2020).
doi: 10.1007/s00247-020-04663-8
pubmed: 32409910
Dillman, J. R. et al. Diagnostic performance of quantitative magnetic resonance imaging biomarkers for predicting portal hypertension in children and young adults with autoimmune liver disease. Pediatr. Radiol. 49, 332–341. https://doi.org/10.1007/s00247-018-4319-1 (2019).
doi: 10.1007/s00247-018-4319-1
pubmed: 30607435
pmcid: 8530173
Levick, C. et al. Non-invasive assessment of portal hypertension by multi-parametric magnetic resonance imaging of the spleen: A proof of concept study. PLoS One. 14, e0221066. https://doi.org/10.1371/journal.pone.0221066 (2019).
doi: 10.1371/journal.pone.0221066
pubmed: 31430314
pmcid: 6701782
Jayaswal, A. N. A. et al. Prognostic value of multiparametric magnetic resonance imaging, transient elastography and blood-based fibrosis markers in patients with chronic liver disease. Liver Int. Off. J. Int. Assoc. Study Liver. 40, 3071–3082. https://doi.org/10.1111/liv.14625 (2020).
doi: 10.1111/liv.14625
Harrison, S. A. et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Lond. Engl. 394, 2012–2024. https://doi.org/10.1016/S0140-6736(19)32517-6 (2019).
doi: 10.1016/S0140-6736(19)32517-6
Harrison, S. A. et al. Safety, tolerability, and biologic activity of AXA1125 and AXA1957 in subjects with nonalcoholic fatty liver disease. Am. J. Gastroenterol. 116, 2399–2409. https://doi.org/10.14309/ajg.0000000000001375 (2021).
doi: 10.14309/ajg.0000000000001375
pubmed: 34382947
pmcid: 8631161
Harrison, S. A. et al. Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial. PLoS One. 13, e0203054. https://doi.org/10.1371/journal.pone.0203054 (2018).
doi: 10.1371/journal.pone.0203054
pubmed: 30192782
pmcid: 6128474
Harrison, S. A. et al. NGM282 improves liver fibrosis and histology in 12 weeks in patients with nonalcoholic steatohepatitis. Hepatol. 71, 1198–1212. https://doi.org/10.1002/hep.30590 (2020).
doi: 10.1002/hep.30590
McKay, A. et al. Patient understanding and experience of non-invasive imaging diagnostic techniques and the liver patient pathway. J. Patient-Rep. Outcomes. 5, 89. https://doi.org/10.1186/s41687-021-00363-5 (2021).
doi: 10.1186/s41687-021-00363-5
pubmed: 34508298
pmcid: 8433277
Imajo, K. et al. Quantitative multiparametric magnetic resonance imaging can aid non-alcoholic steatohepatitis diagnosis in a Japanese cohort. World J. Gastroenterol. 27, 609–623. https://doi.org/10.3748/wjg.v27.i7.609 (2021).
doi: 10.3748/wjg.v27.i7.609
pubmed: 33642832
pmcid: 7901049
Mojtahed, A. et al. Repeatability and reproducibility of deep-learning-based liver volume and Couinaud segment volume measurement tool. Abdom. Radiol. N. Y. 47, 143–151. https://doi.org/10.1007/s00261-021-03262-x (2022).
doi: 10.1007/s00261-021-03262-x
Wilman, H. R. et al. Characterisation of liver fat in the UK Biobank cohort. PLoS One. 12, e0172921. https://doi.org/10.1371/journal.pone.0172921 (2017).
doi: 10.1371/journal.pone.0172921
pubmed: 28241076
Pan, J.-J. & Fallon, M. B. Gender and racial differences in nonalcoholic fatty liver disease. World J. Hepatol. 6, 274–283. https://doi.org/10.4254/wjh.v6.i5.274 (2014).
doi: 10.4254/wjh.v6.i5.274
pubmed: 24868321
pmcid: 4033285
Villavicencio, E. A. Communicating PNPLA3 genetic risk status for NAFLD among Mexican-origin men. Front. Public Health. 10, 1090101. https://doi.org/10.3389/fpubh.2022.1090101 (2023).
doi: 10.3389/fpubh.2022.1090101
pubmed: 36684893
pmcid: 9846364
Newton, K. P. et al. Nonalcoholic steatohepatitis clinical research network. Prevalence of prediabetes and type 2 diabetes in children with nonalcoholic fatty liver disease. JAMA Pediatr. 170, e161971. https://doi.org/10.1001/jamapediatrics.2016.1971 (2016).
doi: 10.1001/jamapediatrics.2016.1971
pubmed: 27478956
pmcid: 5479314
Cioffi, C. E. et al. Natural history of NAFLD diagnosed in childhood: a single-center study. Children 4, Article 34. https://doi.org/10.3390/children4050034 (2017).
doi: 10.3390/children4050034
Simon, T. G., Roelstraete, B., Khalili, H., Hagström, H. & Ludvigsson, J. F. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. Gut 70, 1375–1382. https://doi.org/10.1136/gutjnl-2020-322786 (2021).
doi: 10.1136/gutjnl-2020-322786
pubmed: 33037056
European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO); European Association for the Study of the Liver (EASL). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J. Hepatol. 81, 492–542. https://doi.org/10.1016/j.jhep.2024.04.031 (2024).
Kuczmarski, R.J. et al. 2000 CDC Growth Charts for the United States: methods and development. Vital Health Stat. 11, 1–190. https://stacks.cdc.gov/view/cdc/6451 (2002).
Kadam, P. & Bhalerao, S. Sample size calculation. Int. J. Ayurveda Res. 1, 55–57. https://doi.org/10.4103/0974-7788.59946 (2010).
doi: 10.4103/0974-7788.59946
pubmed: 20532100
pmcid: 2876926
Harrison, S. A. et al. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort. J. Hepatol. 75, 284–291. https://doi.org/10.1016/j.jhep.2021.02.034 (2021).
doi: 10.1016/j.jhep.2021.02.034
pubmed: 33746083
American Diabetes Association Professional Practice Committee. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022. Diabetes Care. 45, S17–S38. https://doi.org/10.2337/dc22-S002 (2022).
Ahrens, W. et al. Metabolic syndrome in young children: definitions and results of the IDEFICS study. Int. J. Obes. 38(Suppl 2), S4-14. https://doi.org/10.1038/ijo.2014.130 (2014).
doi: 10.1038/ijo.2014.130
Andersson, A. et al. Clinical utility of MRI biomarkers for identifying NASH patients’ high risk of progression: A multi-center pooled data and meta-analysis. Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc. 20, 2451–2461. https://doi.org/10.1016/j.cgh.2021.09.041 (2021).
Bachtiar, V. et al. Repeatability and reproducibility of multiparametric magnetic resonance imaging of the liver. PLoS One. 14, e0214921. https://doi.org/10.1371/journal.pone.0214921 (2019).
doi: 10.1371/journal.pone.0214921
pubmed: 30970039
pmcid: 6457552
Yu, E. L. & Schwimmer, J. B. Epidemiology of pediatric nonalcoholic fatty liver disease. Clin. Liver. Dis. 17, 196–199. https://doi.org/10.1002/cld.1027 (2021).
doi: 10.1002/cld.1027
Simon, T. G. et al. Non-alcoholic fatty liver disease in children and young adults is associated with increased long-term mortality. J. Hepatol. 75, 1034–1041. https://doi.org/10.1016/j.jhep.2021.06.034 (2021).
doi: 10.1016/j.jhep.2021.06.034
pubmed: 34224779
pmcid: 8530955
Fuji, H. et al. Clinical outcomes in biopsy-proven nonalcoholic fatty liver disease patients: a multicenter registry-based cohort study. Clin. Gastroenterol. Hepatol. 21, 370–379. https://doi.org/10.1016/j.cgh.2022.01.002 (2022).
doi: 10.1016/j.cgh.2022.01.002
O’Hara, J. et al. Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study. JHEP Rep. 2, 100142. https://doi.org/10.1016/j.jhepr.2020.100142 (2020).
doi: 10.1016/j.jhepr.2020.100142
pubmed: 32775976
pmcid: 7397699
Cusi, K. et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr. Pract. Off. J. Am. Coll. Endocrinol. Am. Assoc. Clin. Endocrinol. 28, 528–562. https://doi.org/10.1016/j.eprac.2022.03.010 (2022).
doi: 10.1016/j.eprac.2022.03.010
Long, M. T., Noureddin, M. & Lim, J. K. AGA clinical practice update: diagnosis and management of nonalcoholic fatty liver disease in lean individuals: expert review. Gastroenterology. 163, 764–774. https://doi.org/10.1053/j.gastro.2022.06.023 (2022).
doi: 10.1053/j.gastro.2022.06.023
pubmed: 35842345
Anderson, E. L. et al. The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis. PloS One. 10, e0140908. https://doi.org/10.1371/journal.pone.0140908 (2015).
doi: 10.1371/journal.pone.0140908
pubmed: 26512983
pmcid: 4626023
Pavlides, M. et al. Multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease severity. Liver. Int. 37, 1065–1073. https://doi.org/10.1111/liv.13284 (2017).
doi: 10.1111/liv.13284
pubmed: 27778429
pmcid: 5518289
Eddowes, P. J. et al. Utility and cost evaluation of multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 47, 631–644. https://doi.org/10.1111/apt.14469 (2018).
doi: 10.1111/apt.14469
pubmed: 29271504
Baratta, F. et al. Nonalcoholic fatty liver disease and fibrosis associated with increased risk of cardiovascular events in a prospective study. Clin. Gastroenterol. Hepatol. 18, 2324–2331. https://doi.org/10.1007/s11739-012-0819-4 (2020).
doi: 10.1007/s11739-012-0819-4
pubmed: 31887443
Newsome, P. N. et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N. Engl. J. Med. 384, 1113–1124. https://doi.org/10.1056/NEJMoa2028395 (2021).
doi: 10.1056/NEJMoa2028395
pubmed: 33185364
Jiménez-Cortegana, C. et al. Role of leptin in non-alcoholic fatty liver disease. Biomedicines. 9, 762. https://doi.org/10.3390/biomedicines9070762 (2021).
doi: 10.3390/biomedicines9070762
pubmed: 34209386
pmcid: 8301314
Sammer, M. B. K. et al. Use of artificial intelligence in radiology: impact on pediatric patients, a white paper from the ACR pediatric AI workgroup. J. Am. Coll. Radiol. 20, 730–737. https://doi.org/10.1016/j.jacr.2023.06.003 (2023).
doi: 10.1016/j.jacr.2023.06.003
pubmed: 37498259
Muratori, L., Lohse, A. W. & Lenzi, M. Diagnosis and management of autoimmune hepatitis. BMJ. 380, e070201. https://doi.org/10.1136/bmj-2022-070201 (2023).
doi: 10.1136/bmj-2022-070201
pubmed: 36746473
Carrion, A. F., Ghanta, R., Carrasquillo, O. & Martin, P. Chronic liver disease in the hispanic population of the United States. Clin. Gastroenterol. Hepatol. 9, 834-e110. https://doi.org/10.1016/j.cgh.2011.04.027 (2014).
doi: 10.1016/j.cgh.2011.04.027
Le Garf, S., Negre, V., Anty, R. & Gual, P. Metabolic fatty liver disease in children: A growing public health problem. Biomedicines. 9, 1–23. https://doi.org/10.3390/biomedicines9121915 (2021).
doi: 10.3390/biomedicines9121915
Shingina, A. et al. Future trends in demand for liver transplant: birth cohort effects among patients with NASH and HCC. Transplantation. 103, 140–148. https://doi.org/10.1097/TP.0000000000002497 (2019).
doi: 10.1097/TP.0000000000002497
pubmed: 30451739